title: Effect of nesiritide in patients with acute decompensated heart failure.
abstract: BACKGROUND
  Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent.
  
  
  METHODS
  We randomly assigned 7141 patients who were hospitalized with acute heart failure to receive either nesiritide or placebo for 24 to 168 hours in addition to standard care. Coprimary end points were the change in dyspnea at 6 and 24 hours, as measured on a 7-point Likert scale, and the composite end point of rehospitalization for heart failure or death within 30 days.
  
  
  RESULTS
  Patients randomly assigned to nesiritide, as compared with those assigned to placebo, more frequently reported markedly or moderately improved dyspnea at 6 hours (44.5% vs. 42.1%, P=0.03) and 24 hours (68.2% vs. 66.1%, P=0.007), but the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. The rate of rehospitalization for heart failure or death from any cause within 30 days was 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute difference, -0.7 percentage points; 95% confidence interval [CI], -2.1 to 0.7; P=0.31). There were no significant differences in rates of death from any cause at 30 days (3.6% with nesiritide vs. 4.0% with placebo; absolute difference, -0.4 percentage points; 95% CI, -1.3 to 0.5) or rates of worsening renal function, defined by more than a 25% decrease in the estimated glomerular filtration rate (31.4% vs. 29.5%; odds ratio, 1.09; 95% CI, 0.98 to 1.21; P=0.11).
  
  
  CONCLUSIONS
  Nesiritide was not associated with an increase or a decrease in the rate of death and rehospitalization and had a small, nonsignificant effect on dyspnea when used in combination with other therapies. It was not associated with a worsening of renal function, but it was associated with an increase in rates of hypotension. On the basis of these results, nesiritide cannot be recommended for routine use in the broad population of patients with acute heart failure. (Funded by Scios; ClinicalTrials.gov number, NCT00475852.).
authors: Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27710, USA. oconn002@mc.duke.edu
authors: C M
authors: CM
authors: O'Connor
authors: R C
authors: RC
authors: Starling
authors: A F
authors: AF
authors: Hernandez
authors: P W
authors: PW
authors: Armstrong
authors: K
authors: K
authors: Dickstein
authors: V
authors: V
authors: Hasselblad
authors: G M
authors: GM
authors: Heizer
authors: M
authors: M
authors: Komajda
authors: B M
authors: BM
authors: Massie
authors: J J V
authors: JJ
authors: McMurray
authors: M S
authors: MS
authors: Nieminen
authors: C J
authors: CJ
authors: Reist
authors: J L
authors: JL
authors: Rouleau
authors: K
authors: K
authors: Swedberg
authors: K F
authors: KF
authors: Adams
authors: S D
authors: SD
authors: Anker
authors: D
authors: D
authors: Atar
authors: A
authors: A
authors: Battler
authors: R
authors: R
authors: Botero
authors: N R
authors: NR
authors: Bohidar
authors: J
authors: J
authors: Butler
authors: N
authors: N
authors: Clausell
authors: R
authors: R
authors: Corbalán
authors: M R
authors: MR
authors: Costanzo
authors: U
authors: U
authors: Dahlstrom
authors: L I
authors: LI
authors: Deckelbaum
authors: R
authors: R
authors: Diaz
authors: M E
authors: ME
authors: Dunlap
authors: J A
authors: JA
authors: Ezekowitz
authors: D
authors: D
authors: Feldman
authors: G M
authors: GM
authors: Felker
authors: G C
authors: GC
authors: Fonarow
authors: D
authors: D
authors: Gennevois
authors: S S
authors: SS
authors: Gottlieb
authors: J A
authors: JA
authors: Hill
authors: J E
authors: JE
authors: Hollander
authors: J G
authors: JG
authors: Howlett
authors: M P
authors: MP
authors: Hudson
authors: R D
authors: RD
authors: Kociol
authors: H
authors: H
authors: Krum
authors: A
authors: A
authors: Laucevicius
authors: W C
authors: WC
authors: Levy
authors: G F
authors: GF
authors: Méndez
authors: M
authors: M
authors: Metra
authors: S
authors: S
authors: Mittal
authors: B-H
authors: BH
authors: Oh
authors: N L
authors: NL
authors: Pereira
authors: P
authors: P
authors: Ponikowski
authors: W H W
authors: WH
authors: Tang
authors: W H
authors: WH
authors: Wilson
authors: S
authors: S
authors: Tanomsup
authors: J R
authors: JR
authors: Teerlink
authors: F
authors: F
authors: Triposkiadis
authors: R W
authors: RW
authors: Troughton
authors: A A
authors: AA
authors: Voors
authors: D J
authors: DJ
authors: Whellan
authors: F
authors: F
authors: Zannad
authors: R M
authors: RM
authors: Califf
mesh_terms: D000208:Acute Disease; D000368:Aged; D004311:Double-Blind Method; D004417:Dyspnea / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D057194:Intention to Treat Analysis; D007674:Kidney Diseases / Q000209:etiology; D008297:Male; D008875:Middle Aged; D045283:Natriuretic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain / Q000009:adverse effects / Q000627:therapeutic use*; D010359:Patient Readmission / Q000706:statistics & numerical data*; D012008:Recurrence
chemical_list: D045283:Natriuretic Agents; D020097:Natriuretic Peptide, Brain